Knightscope amends ATM prospectus to sell up to $35 million in stock
- Knightscope amended its ATM prospectus to offer up to $35 million in Class A common stock
- The amendment adds $32.5 million to the $2.5 million previously authorized but unsold
- The company has already sold $47.5 million in shares under the existing sales agreement
- H.C. Wainwright & Co., LLC continues to act as the sales agent for the offering

*this image is generated using AI for illustrative purposes only.
Knightscope has amended its At-the-Market (ATM) offering prospectus to increase the total amount of Class A common stock it intends to sell to $35,000,000. The filing, which supplements a base prospectus dated April 11, 2025, allows the security automation firm to raise additional capital through its ongoing sales agreement with H.C. Wainwright & Co., LLC.
The amendment expands the authorized offering by $32,495,466.64 beyond the amount previously authorized under the July 18, 2025 ATM Prospectus Supplement. This brings the total new authorization to $35 million, consisting of $2,504,533.36 from the prior supplement and the newly added funds.
Offering Details
The shares are being offered pursuant to an At-the-Market Offering Agreement dated February 1, 2023. Under this arrangement, H.C. Wainwright acts as the sales agent or principal. The Class A common stock carries a par value of $0.001 per share.
| Metric | Amount |
|---|---|
| Total New Authorization | $35,000,000 |
| Additional Amount Authorized | $32,495,466.64 |
| Previously Authorized (Unsold) | $2,504,533.36 |
Historical Sales Context
Since inception of the current sales agreement, Knightscope has already sold an aggregate of $47,495,466.64 worth of Class A common stock through the sales agent. The new amendment does not affect these previously sold shares but adds to the pool of shares available for future issuance.
The registration statement associated with this offering is filed on Form S-3 (File No. 333-286404). The prospectus supplement must be read in conjunction with the base prospectus and is not complete without it.
How will the $35 million in newly authorized capital specifically impact Knightscope's R&D roadmap for autonomous security solutions?
What is the expected timeline for completing the sale of these additional shares, and how might market volatility influence the execution pace?
To what extent will this equity issuance dilute existing shareholders, and how does management plan to offset potential EPS pressure?































